Earnings summaries and quarterly performance for Kymera Therapeutics.
Executive leadership at Kymera Therapeutics.
Nello Mainolfi
Detailed
President and Chief Executive Officer
CEO
BA
Brian Adams
Detailed
Chief Legal Officer and Corporate Secretary
BJ
Bruce Jacobs
Detailed
Chief Financial Officer
JG
Jared Gollob
Detailed
Chief Medical Officer
JC
Jeremy Chadwick
Detailed
Chief Operating Officer
NG
Noah Goodman
Detailed
Chief Business Officer
Board of directors at Kymera Therapeutics.
Research analysts who have asked questions during Kymera Therapeutics earnings calls.
Andy Chen
Wolfe Research, LLC
4 questions for KYMR
Also covers: ARGX, CRNX, IMVT +7 more
Faisal Khurshid
Leerink Partners
4 questions for KYMR
Also covers: ABCL, ANIP, GERN +4 more
JM
Jeet Mukherjee
Leerink Partners
3 questions for KYMR
Also covers: ARVN, BCAB, KURA +4 more
Jeff Jones
Oppenheimer & Co. Inc.
3 questions for KYMR
Also covers: ABEO, CLRB, CMMB +8 more
MF
Marc Frahm
TD Cowen
3 questions for KYMR
Also covers: ADAP, AGIO, BPMC +7 more
BC
Bradley Canino
Stifel
2 questions for KYMR
Also covers: ARVN, CELC, KURA +2 more
EM
Eliana Merle
UBS
2 questions for KYMR
Also covers: ALNY, APLS, ARVN +17 more
Eric Joseph
JPMorgan Chase & Co.
2 questions for KYMR
Also covers: BEAM, BLUE, ENTA +9 more
KP
Kalpit Patel
B. Riley Securities
2 questions for KYMR
Also covers: DERM, FBRX, GERN +4 more
Kelly Shi
Jefferies
2 questions for KYMR
Also covers: ADCT, AGEN, ALDX +17 more
Michael Schmidt
Guggenheim Securities
2 questions for KYMR
Also covers: ADAP, ADCT, ARVN +19 more
Paul Jeng
Guggenheim Partners
2 questions for KYMR
Also covers: ADAP, BPMC, IMCR +2 more
SL
Sudan Loganathan
Stephens Inc.
2 questions for KYMR
Also covers: ADCT, ARVN, BPMC +6 more
AS
Alexei Siniakov
Truist Securities
1 question for KYMR
Alex Thompson
Stifel Financial Corp.
1 question for KYMR
Also covers: ARGX, ASND, CRNX +1 more
AN
Andrea Newkirk
Goldman Sachs
1 question for KYMR
Also covers: ABCL, ALKS, ARWR +9 more
Derek Archila
Wells Fargo
1 question for KYMR
Also covers: APLS, ARGX, ARVN +9 more
DS
Dingding Shi
Jefferies
1 question for KYMR
Also covers: ADCT, ASND, AUTL +6 more
EM
Ellie Merle
UBS Group AG
1 question for KYMR
Also covers: ALNY, ALT, ARVN +12 more
EW
Eric Wong
The Goldman Sachs Group, Inc.
1 question for KYMR
Eva Fortea-Verdejo
Wells Fargo Securities
1 question for KYMR
Also covers: EXEL, KNSA, RCUS
GE
Gospel Enyindah-Asonye
Morgan Stanley
1 question for KYMR
Also covers: RGNX, VTYX
Judah Frommer
Morgan Stanley
1 question for KYMR
Also covers: APLS, ARQT, ATAI +4 more
KD
Kripa Devarakonda
Truist Securities
1 question for KYMR
Also covers: ABCL, ARVN, BMY +5 more
Mayank Mamtani
B. Riley Securities
1 question for KYMR
Also covers: AGEN, ALT, ARWR +18 more
Parth Patel
Morgan Stanley
1 question for KYMR
Also covers: AXSM
RF
Ron Feiner
Leerink Partners
1 question for KYMR
Also covers: WVE
Sam Slutsky
LifeSci Capital, LLC
1 question for KYMR
Also covers: ALXO, PVLA, RAIN +1 more
SD
Srikripa Devarakonda
Truist Financial Corporation
1 question for KYMR
Also covers: ABCL, ABSI, AFMD +12 more
TA
Tazeen Ahmad
Bank of America
1 question for KYMR
Also covers: ACAD, ALNY, APLS +20 more
VP
Vikram Purohit
Morgan Stanley
1 question for KYMR
Also covers: ABSI, ARGX, ARQT +11 more
Recent press releases and 8-K filings for KYMR.
Kymera Therapeutics Highlights 2025 Achievements and 2026 Outlook at J.P. Morgan Healthcare Conference
KYMR
Guidance Update
New Projects/Investments
- Kymera Therapeutics, celebrating its 10-year anniversary in May 2025, is focused on developing oral drugs with biologics-like activity, primarily in immunology.
- In 2025, the company completed early clinical translation of its KT-621 (STAT6 program), demonstrating full pathway blockade of IL-4 and IL-13 in humans, and initiated two Phase 2b studies for AD and asthma in late 2025/early 2026, with data expected in 2027.
- Kymera raised almost $1 billion in 2025, bringing its total cash to approximately $1.6 billion, which is projected to fund the company through at least 2029.
- For 2026, the company plans to initiate a Phase 1 study for its IRF5 degrader KT-579, with data expected in the second half of the year, and will continue to advance its partnered programs and disclose a new immunology program.
1 day ago
Kymera Therapeutics Updates on Clinical Pipeline Progress and Financial Outlook
KYMR
New Projects/Investments
Guidance Update
- Kymera Therapeutics reported positive Phase 1b data for KT-621 (STAT6 degrader) in Atopic Dermatitis (AD) in December 2025, demonstrating robust reductions in EASI, SCORAD, and itch, and significant FeNO reduction in comorbid asthma patients. The company is advancing the BROADEN2 Phase 2b AD trial (data expected mid-2027) and initiated the BREADTH Phase 2b asthma study in January 2026 (data expected late-2027).
- Kymera plans to initiate a Phase 1 healthy volunteer trial for KT-579 (IRF5 degrader) in Q1 2026, with data expected in 2H 2026.
- The company is well-capitalized with $1.6 billion in cash, providing a runway into 2029. Additionally, Sanofi opted-in to KT-485 with plans to advance it into Phase 1 testing in 2026, and Kymera is collaborating with Gilead on a CDK2 molecular glue degrader program.
1 day ago
Kymera Therapeutics Provides 2026 Outlook and Program Updates
KYMR
New Projects/Investments
Guidance Update
- Kymera Therapeutics announced it has $1.6 billion in funding, projected to last through 2029, which will enable the company to advance several programs through proof of concept and Phase 2 studies, and KT-621 into Phase 3 studies.
- The company initiated two Phase 2b studies for its lead program, KT-621, in atopic dermatitis (late 2025) and asthma (early 2026), with data from both studies expected in 2027.
- Kymera plans to initiate a Phase 1 study for its IRF5 degrader KT-579 soon, with Phase 1 data anticipated in the second half of 2026, and is on track to advance a second-generation IRAK4 degrader, KT-485, with Sanofi into Phase 1 this year.
- The company's strategy focuses on developing oral drugs with biologics-like activity for undrugged targets in immunology, aiming to transform how patients with immune-inflammatory diseases are treated.
1 day ago
Kymera Therapeutics Provides 2026 Outlook and Pipeline Updates at J.P. Morgan Healthcare Conference
KYMR
New Projects/Investments
Guidance Update
- Kymera Therapeutics has approximately $1.6 billion in funding, projected to last through at least 2029, enabling the advancement of several programs through proof of concept and Phase 2 studies, and KT-621 into Phase 3.
- The company initiated Phase 2b studies for its lead program, KT-621, in atopic dermatitis (AD) (late 2025) and asthma (early 2026), with data from both studies anticipated in 2027.
- Kymera is on track to initiate a Phase 1 study for its IRF5 degrader KT-579 in early 2026, with Phase 1 data anticipated in the second half of 2026, and is progressing its collaborations with Sanofi and Gilead.
- A new immunology program is expected to be disclosed and enter IND-enabling studies later in 2026.
1 day ago
Kymera Therapeutics Outlines 2026 Objectives and Strong Cash Position
KYMR
Guidance Update
New Projects/Investments
Earnings
1 day ago
Kymera Therapeutics Announces 2026 Milestones and Strong Cash Position
KYMR
Guidance Update
New Projects/Investments
- Kymera Therapeutics outlined its 2026 preclinical and clinical milestones for its oral immunology pipeline, highlighting its strong financial position with an estimated $1.6 billion in cash as of December 31, 2025, providing a runway into 2029.
- For the STAT6 Degrader Program, the KT-621 BROADEN2 Phase 2b trial in AD is ongoing with data expected by mid-2027, and the KT-621 BREADTH Phase 2b trial in asthma has been initiated, with data expected in late-2027.
- The KT-579 Phase 1 healthy volunteer clinical trial is projected to begin in 1Q26, with data anticipated in 2H26.
- The company also aims to advance at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026.
1 day ago
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities
KYMR
Product Launch
New Projects/Investments
Board Change
- Kyverna Therapeutics anticipates submitting a Biologics License Application (BLA) for miv-cel in stiff person syndrome (SPS) in 1H 2026, aiming to be first-to-market.
- The company strengthened its financial position by raising approximately $105 million in gross proceeds from a follow-on offering in December 2025, extending its cash runway into 2028. Estimated cash, cash equivalents, and marketable securities as of December 31, 2025, were approximately $279 million.
- The first patient was enrolled in the registrational Phase 3 trial for generalized myasthenia gravis (gMG) in December 2025.
- Christi Shaw was appointed as Executive Chairperson of the Board in January 2026, bringing significant CAR T-cell therapy experience.
3 days ago
Kymera Therapeutics Closes Upsized Public Offering
KYMR
New Projects/Investments
- Kymera Therapeutics closed its upsized underwritten public offering of $602.0 million of common stock.
- The offering included the full exercise by the underwriters of their option to purchase additional shares.
- A total of 8,050,000 shares of common stock were sold at a public offering price of $86.00 per share.
- The gross proceeds to Kymera from the offering were approximately $692.3 million before deducting underwriting discounts and estimated offering expenses.
Dec 11, 2025, 9:01 PM
Kymera Therapeutics Receives FDA Fast Track Designation for KT-621
KYMR
Product Launch
New Projects/Investments
- Kymera Therapeutics announced that the U.S. FDA has granted Fast Track designation to KT-621, its first-in-class, oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis (AD).
- This designation is supported by positive results from the KT-621 BroADen Phase 1b AD patient trial.
- The BROADEN2 Phase 2b AD trial is ongoing, with data expected by mid-2027, and the BREADTH Phase 2b trial in asthma is planned to initiate in Q1 2026.
- The Fast Track designation is intended to accelerate the development and review of therapies for serious conditions with unmet medical needs, potentially leading to faster market access.
Dec 11, 2025, 12:00 PM
Kymera Therapeutics Announces Pricing of Upsized Public Offering and Full Option Exercise
KYMR
- Kymera Therapeutics announced the pricing of its underwritten public offering, selling 7,000,000 shares of common stock at a public offering price of $86.00 per share.
- The underwriters exercised their option in full on December 10, 2025, to purchase an additional 1,050,000 shares of common stock.
- The company expects to receive estimated net proceeds of approximately $656.1 million from the offering.
- The offering is expected to close on December 11, 2025.
- Net proceeds will be used to advance its pipeline of preclinical and clinical degrader programs, and for working capital and other general corporate purposes.
Dec 10, 2025, 10:17 PM
Quarterly earnings call transcripts for Kymera Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more